Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LGND
  • CUSIP: 53220K50
  • Web:
  • Market Cap: $2.39 billion
  • Outstanding Shares: 20,996,000
Average Prices:
  • 50 Day Moving Avg: $109.36
  • 200 Day Moving Avg: $106.14
  • 52 Week Range: $87.50 - $139.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.80
  • P/E Growth: 1.20
Sales & Book Value:
  • Annual Revenue: $108.59 million
  • Price / Sales: 22.01
  • Book Value: $18.99 per share
  • Price / Book: 5.99
  • EBIDTA: $51.73 million
  • Net Margins: 8.51%
  • Return on Equity: 9.98%
  • Return on Assets: 5.56%
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 0.62%
  • Quick Ratio: 0.60%
  • Average Volume: 256,384 shs.
  • Beta: 1.39
  • Short Ratio: 12.42

Frequently Asked Questions for Ligand Pharmaceuticals (NASDAQ:LGND)

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its earnings results on Tuesday, May, 9th. The company reported $0.39 EPS for the quarter, missing the Zacks' consensus estimate of $0.55 by $0.16. The company earned $29.27 million during the quarter, compared to analysts' expectations of $30.25 million. Ligand Pharmaceuticals had a return on equity of 9.98% and a net margin of 8.51%. Ligand Pharmaceuticals's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 EPS. View Ligand Pharmaceuticals' Earnings History.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $2.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.12.

Where is Ligand Pharmaceuticals' stock going? Where will Ligand Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1 year price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $105.00 to $160.00. On average, they expect Ligand Pharmaceuticals' share price to reach $134.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.

Who are some of Ligand Pharmaceuticals' key competitors?

Who owns Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.50%), William Blair Investment Management LLC (8.26%), Vanguard Group Inc. (8.07%), Knott David M (4.77%), State Street Corp (4.06%) and Victory Capital Management Inc. (3.26%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, David M Knott, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Who sold Ligand Pharmaceuticals stock? Who is selling Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Victory Capital Management Inc., Kalmar Investments Inc. DE, Hood River Capital Management LLC, FMR LLC, Ameriprise Financial Inc., Morgan Stanley and Nationwide Fund Advisors. Company insiders that have sold Ligand Pharmaceuticals stock in the last year include Jason Aryeh, John L Higgins, John W Kozarich and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals.

Who bought Ligand Pharmaceuticals stock? Who is buying Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., William Blair Investment Management LLC, Renaissance Technologies LLC, Gotham Asset Management LLC, Vanguard Group Inc., Cortina Asset Management LLC, Macquarie Group Ltd. and Stephens Investment Management Group LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy Ligand Pharmaceuticals stock?

Shares of Ligand Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ligand Pharmaceuticals stock cost?

One share of Ligand Pharmaceuticals stock can currently be purchased for approximately $113.82.

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $134.00 (17.73% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Roth CapitalSet Price TargetBuy$120.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00N/AView Rating Details
10/5/2016HC WainwrightReiterated RatingBuy$146.00 -> $160.00N/AView Rating Details
9/7/2016Deutsche Bank AGUpgradeSell -> Hold$110.00 -> $105.00N/AView Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Earnings History by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Trades by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ligand Pharmaceuticals (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline logoLigand Pharmaceuticals Inc. (LGND) PT Set at $120.00 by Roth Capital - May 23 at 6:58 PM logoETFs with exposure to Ligand Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 5:39 PM logoLigand to Participate in Two Upcoming Investor Conferences - May 22 at 10:21 AM logoLigand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 10:49 AM logoMatthew W. Foehr Sells 5,621 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock - May 15 at 10:35 PM logoLigand Pharmaceuticals Inc. (LGND) Lowered to Strong Sell at Zacks Investment Research - May 15 at 9:14 AM logoLigand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sells 37,247 Shares - May 13 at 7:22 AM logoLigand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates - Nasdaq - May 11 at 6:46 PM logoLigand Pharmaceuticals Inc Q1 Earnings Fall 7% - May 10 at 12:52 PM logoLigand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates - May 10 at 12:52 PM logoEdited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 12:52 PM logoLigand Pharmaceuticals Inc. (LGND) Posts Earnings Results, Misses Estimates By $0.15 EPS - May 9 at 10:44 PM logoLigand Pharmaceuticals Inc. (LGND) Issues FY17 Earnings Guidance - May 9 at 6:25 PM logoInvestor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - May 9 at 6:01 PM logoLigand Reports First Quarter 2017 Financial Results - May 9 at 6:01 PM logoLigand posts 1Q profit - May 9 at 5:21 PM logoLigand Pharmaceuticals Inc. (LGND) Given Average Recommendation of "Buy" by Analysts - May 6 at 12:35 AM logo$30.43 Million in Sales Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter - May 4 at 2:18 PM logoVery Favorable Press Coverage Extremely Likely to Affect Ligand Pharmaceuticals (LGND) Stock Price - May 3 at 1:46 PM logo Brokerages Expect Ligand Pharmaceuticals Inc. (LGND) to Post $0.65 EPS - May 2 at 9:06 AM logoLigand Pharmaceuticals Inc. (LGND) Upgraded by Zacks Investment Research to Hold - May 1 at 11:02 PM logoLigand Pharmaceuticals (LGND) Receives News Impact Rating of 0.04 - April 30 at 4:11 PM logoLigand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : April 27, 2017 - April 27 at 6:51 PM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : April 26, 2017 - April 26 at 7:03 PM logoSomewhat Negative Press Coverage Very Likely to Affect Ligand Pharmaceuticals (LGND) Share Price - April 26 at 11:14 AM logoLGND Makes Bullish Cross Above Critical Moving Average - April 25 at 5:41 PM logoSomewhat Positive Media Coverage Very Likely to Impact Ligand Pharmaceuticals (LGND) Share Price - April 14 at 10:49 PM logo Brokerages Expect Ligand Pharmaceuticals Inc. (LGND) Will Announce Quarterly Sales of $32.86 Million - April 13 at 1:50 PM logoLigand to Report First Quarter 2017 Results on May 9th - April 13 at 9:12 AM logo$0.65 EPS Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter - April 11 at 9:37 AM logoLigand Pharmaceuticals Inc. (LGND) Short Interest Down 1.0% in March - April 10 at 4:16 PM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : April 10, 2017 - April 10 at 10:42 AM logoLigand Pharma (LGND) Announces Commercial License and Supply Agreements with Marinus Pharmaceuticals (MRNS) for Captisol-Enabled Ganaxolone - April 7 at 10:50 AM logoLigand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone - April 7 at 10:50 AM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 28, 2017 - March 28 at 10:48 AM logoLigand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology - March 28 at 10:48 AM logo9:03 am Ligand Pharma announces that an affiliate of Johnson & Johnson (JNJ) subsidiary Janssen has filed an IND for an antibody discovered using Ligand's OmniAb technology; IND filing results in a $1 mln - March 28 at 10:48 AM logo3 Least Risky Biotech Stocks on the Market - March 28 at 8:19 AM logoLigand Pharmaceuticals Inc. (LGND) CEO John L. Higgins Sells 4,000 Shares - March 21 at 7:39 PM logoLigand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND - March 10 at 7:29 PM logoLigand to Participate in Upcoming Investor Conference - March 9 at 9:02 AM logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US : March 7, 2017 - March 7 at 10:42 AM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events - March 3 at 6:14 PM logoLIGAND PHARMACEUTICALS INC Financials - March 3 at 6:14 PM logoHealth Care Sector Update for 03/01/2017: LGND,DVAX,IPXL ... - Nasdaq - March 3 at 4:33 AM logoNoteworthy Thursday Option Activity: LGND, LXRX, REGN - March 2 at 6:33 PM logoSermonix Says It Secured Worldwide Rights to Oral Lasofoxifene From Ligand Pharma (LGND) - February 28 at 6:24 PM logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - February 28 at 6:24 PM logoLigand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene - February 28 at 6:24 PM logo4:04 pm Ligand Pharma expands its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene - February 28 at 6:24 PM



Ligand Pharmaceuticals (LGND) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff